Oppenheimer expects launch of CTI BioPharma’s rare blood cancer treatment pacritinib to be delayed until 2022

11:32 EDT 18 Jul 2018 | Proactive Investors

As a result, analyst Leah Rush Cann lowered her target price on the biotech stock to US$4 per share from US$6

More From BioPortfolio on "Oppenheimer expects launch of CTI BioPharma’s rare blood cancer treatment pacritinib to be delayed until 2022"